ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable residual disease (MRD)-negative responses in the first four patients with relapsed ...
After a disappointing phase 1 showing, Janux Therapeutics is kicking one of its bispecific T-cell engagers (TCEs) ...
The Brighterside of News on MSN
Study finds low-dose CAR T therapy can drive complete cancer remission
A bone marrow transplant can buy time for people with aggressive B-cell cancers. Too often, it does not buy enough. For ...
CAR T-cell therapy has transformed the treatment of hematologic malignancies, yet many patients do not achieve lasting ...
Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to PlanOral Minisymposium Presentation Demonstrates That EVOLVE T Cell ...
Stem-cell memory T (TSCM) cells are a rare subset of immune cells with the ability to self-renew, persist long term, and ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
A new study published online in the Journal of Intensive Medicine on June 17, 2025, highlights early and dynamic alterations in lymphocyte subsets following sepsis in elderly patients and their ...
There are differences between familial and idiopathic pulmonary fibrosis in terms of cluster of differentiation 20 and CD3 expression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results